EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study

Saira S Mirza iD, Maurice Pasternak iD, Andrew D Paterson iD, Ekaterina Rogaeva, Maria C Tartaglia, Sara B Mitchell, Sandra E Black, Morris Freedman, David Tang-Wai, Arabella Bouzigues, Lucy L Russell, Phoebe H Foster und 32 weitere

Brain · 2025

DOI: 10.1093/brain/awaf019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Saira S Mirza und 43 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON …. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Nerve Tissue Proteins, Membrane Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR), Weston Brain Institute, Centre of Brain Resilience and Recovery (CBRR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Common variants within TMEM106B are associated with risk for frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). The G allele of the top single nucleotide polymorphism, rs1990622, confers protection against FTLD-TDP, including genetic cases due to GRN mutations or C9orf72 hexanucleotide repeat expansions. However, the effects of interaction between TMEM106B-rs1990622 and frontotemporal dementia (FTD) mutations on disease endophenotypes in genetic FTD are unknown. This longitudinal cohort study was embedded within the GENetic Frontotemporal dementia Initiative (GENFI). We included 518 participants from 222 families [209 non-carriers; 222 presymptomatic carriers (C9orf72 = 79; GRN = 101, MAPT = 42); 87 symptomatic carriers (C9orf72 = 45; GRN = 29; MAPT = 13)] followed for up to 7 years. Using linear mixed-effects models, we examined the effects of a triple interaction between TMEM106B-rs1990622G allele dosage (additive model: 0, 1 or 2 alleles) and autosomal dominant FTD mutations with clinical status, and time from baseline on (i) grey matter volume using a voxel-based analysis; (ii) serum neurofilament light chain (NfL) levels; and (iii) cognitive and behavioural measures. Mean age of participants was 47.9 ± 13.8 years, 58.1% were female and 61% had at least one G allele. C9orf72: rs1990622G allele dosage was associated with less atrophy within the right occipital region in presymptomatic carriers at baseline, and reduced atrophy rate within putamen and caudate nucleus, right frontotemporal regions, left cingulate and bilateral insular cortices in symptomatic carriers over time; lower NfL levels in presymptomatic carriers at baseline; better executive functions and language abilities in presymptomatic carriers; and maintained overall cognitive functions and behaviour in symptomatic carriers over time. GRN: rs1990622G allele dosage was associated with reduced grey matter atrophy rate within the right temporal and occipital regions in presymptomatic carriers, and within the right frontal cortex and insula over time in symptomatic carriers; lower serum NfL levels over time in presymptomatic carriers and lower NfL levels at both baseline and over time in symptomatic carriers; and better global cognitive performance at baseline and higher attention/processing speed scores over time in symptomatic carriers. MAPT: rs1990622G allele dosage was associated with reduced grey matter atrophy rate within the right inferior frontal gyrus in symptomatic carriers, but no effects on serum NfL or cognitive/behavioural measures. TMEM106B-rs1990622G allele dosage showed protective effects on multiple endophenotypes predominantly in GRN and C9orf72 groups. Therefore, TMEM106B genotype should be assessed in clinical trials, particularly of GRN- and C9orf72-related genetic FTD, due to its modifying effects on biomarker, imaging, cognitive and clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Frontotemporal DementiaNerve Tissue ProteinsMembrane ProteinsHumansFemaleMaleMiddle AgedLongitudinal StudiesC9orf72 ProteinAgedProgranulinsPolymorphism, Single NucleotideMutationAtrophyAdultCohort StudiesMagnetic Resonance Imaging

Stichwörter der Autor:innen

TMEM106BFTLD-TDPadditive modelblood-based biomarkerscognitionstructural MRI

Substanzen

TMEM106B protein, humanNerve Tissue ProteinsMembrane ProteinsC9orf72 ProteinProgranulinsC9orf72 protein, humanGRN protein, human

Autor:innen und Institutionen

  • Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON M4N 3M5, Canada.
  • L. C. Campbell Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada.
  • Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Memory Clinic, University Health Network, Toronto, ON M5T 2S8, Canada.
  • Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada.

ORCID-Profile: Saira S Mirza, Maurice Pasternak, Andrew D Paterson, Martina Bocchetta, David M Cash, Henrik Zetterberg, Lize C Jiskoot, Harro Seelaar, Raquel Sanchez-Valle, Caroline Graff, Rik Vandenberghe, Alexander Gerhard, Johannes Levin, Florence Pasquier, Simon Ducharme, Matthis Synofzik, Barbara Borroni, Mario Masellis

Förderung

  • Canadian Institutes of Health Research (CIHR)
  • Weston Brain Institute
  • Centre of Brain Resilience and Recovery (CBRR)
  • Sunnybrook Foundation
  • Department of Medicine at Sunnybrook Health Sciences Centre and the University of Toronto
  • Wellcome Trust
  • Cambridge University Centre for Frontotemporal Dementia, the Medical Research Council
  • National Institute for Health Research Cambridge Biomedical Research Centre

Zitieren

APA

Mirza, S. S., Pasternak, M., Paterson, A. D., Rogaeva, E., Tartaglia, M. C., Mitchell, S. B., Black, S. E., Freedman, M., Tang-Wai, D., Bouzigues, A., Russell, L. L., Foster, P. H., Ferry-Bolder, E., Bocchetta, M., Cash, D. M., Zetterberg, H., Sogorb-Esteve, A., van Swieten, J., Jiskoot, L. C., …, & GENetic Frontotemporal dementia Initiative (GENFI) (2025). Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study. Brain. https://doi.org/10.1093/brain/awaf019

Vancouver

Mirza SS, Pasternak M, Paterson AD, Rogaeva E, Tartaglia MC, Mitchell SB, et al. Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study. Brain. 2025. doi:10.1093/brain/awaf019

BibTeX
@article{Mirza2025,
  author = {Mirza, Saira S and Pasternak, Maurice and Paterson, Andrew D and Rogaeva, Ekaterina and Tartaglia, Maria C and Mitchell, Sara B and Black, Sandra E and Freedman, Morris and Tang-Wai, David and Bouzigues, Arabella and Russell, Lucy L and Foster, Phoebe H and Ferry-Bolder, Eve and Bocchetta, Martina and Cash, David M and Zetterberg, Henrik and Sogorb-Esteve, Aitana and van Swieten, John and Jiskoot, Lize C and Seelaar, Harro and Sanchez-Valle, Raquel and Laforce, Robert and Graff, Caroline and Galimberti, Daniela and Vandenberghe, Rik and de Mendonça, Alexandre and Tiraboschi, Pietro and Santana, Isabel and Gerhard, Alexander and Levin, Johannes and Sorbi, Sandro and Otto, Markus and Pasquier, Florence and Ducharme, Simon and Butler, Chris and Le Ber, Isabelle and Finger, Elizabeth and Rowe, James B and Synofzik, Matthis and Moreno, Fermin and Borroni, Barbara and Rohrer, Jonathan D and Masellis, Mario and GENetic Frontotemporal dementia Initiative (GENFI), GENetic Frontotemporal dementia Initiative (GENFI)},
  title = {Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awaf019}
}
Kostenlos starten →